Tirzepatide is a synthetic peptide that functions as a dual agonist at both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R), earning the designation “twincretin.” Its clinical profile in type 2 diabetes mellitus (T2DM) and obesity surpasses that of selective GLP-1R agonists across multiple metabolic endpoints, reflecting the additive and partially distinct signaling contributions of the two incretin receptors when activated simultaneously.
The structural basis of tirzepatide’s dual activity lies in its design as a single thirty-nine amino acid peptide with a fatty diacid moiety attached via a linker to lysine at position 26, enabling albumin binding that extends its half-life to approximately five days and permits once-weekly subcutaneous administration. The peptide backbone is derived from the native glucose-dependent insulinotropic polypeptide (GIP) sequence but incorporates amino acid substitutions that confer balanced agonist activity at both GIPR and GLP-1R. At lower doses tirzepatide activates both receptors with roughly equivalent potency; at higher doses GIPR agonism predominates. This receptor-binding profile distinguishes tirzepatide from GLP-1R agonists such as semaglutide, which have no intrinsic GIPR activity.1
The mechanistic rationale for dual incretin receptor agonism rests on the complementary and partially non-overlapping signaling consequences of activating GIPR and GLP-1R simultaneously. GLP-1R agonism drives glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via central nervous system (CNS) pathways. GIPR agonism in the context of concurrent GLP-1R activation adds incremental insulin secretion, enhances glucagon suppression, promotes adipocyte lipid storage and triglyceride clearance, and appears to modulate hypothalamic appetite circuits through GIPR expressed in arcuate nucleus neurons. The adipocyte effect is particularly relevant to the weight loss advantage of tirzepatide: GIPR agonism in adipose tissue increases fat cell insulin sensitivity and triglyceride uptake, reducing circulating free fatty acids and improving the metabolic milieu in a manner not achievable with GLP-1R agonism alone.2
The Semaglutide and Tirzepatide in Type 2 Diabetes (SURPASS) trial program comprised five phase 3 randomized controlled trials (SURPASS-1 through SURPASS-5) evaluating tirzepatide across the spectrum of T2DM management, plus the Semaglutide and Tirzepatide in Type 2 Diabetes – Cardiovascular Outcomes Trial (SURPASS-CVOT). In the Semaglutide and Tirzepatide in Type 2 Diabetes 2 trial (SURPASS-2), which directly compared tirzepatide 5 mg, 10 mg, and 15 mg weekly against semaglutide 1 mg weekly in 1,879 patients with T2DM inadequately controlled on metformin, tirzepatide at all three doses produced greater reductions in glycated hemoglobin (HbA1c) than semaglutide: mean HbA1c reductions were 2.01%, 2.24%, and 2.30% for tirzepatide 5, 10, and 15 mg respectively, compared with 1.86% for semaglutide 1 mg. Body weight reductions at 40 weeks were 7.8 kg, 10.3 kg, and 12.4 kg for the three tirzepatide doses versus 6.2 kg for semaglutide.3
The Surmounting Obesity (SURMOUNT) program evaluated tirzepatide for obesity in patients without T2DM. In the Surmounting Obesity 1 trial (SURMOUNT-1), 2,539 adults with obesity or overweight with at least one weight-related complication (but without T2DM) were randomized to tirzepatide 5 mg, 10 mg, or 15 mg weekly or placebo for 72 weeks. Mean weight loss at 72 weeks was 15.0%, 19.5%, and 20.9% for the three doses versus 3.1% for placebo; 37% of participants receiving tirzepatide 15 mg achieved at least 25% body weight reduction, a magnitude of weight loss previously achievable only with bariatric surgery.4 The Surmounting Obesity 2 trial (SURMOUNT-2) evaluated tirzepatide in patients with both obesity and T2DM, demonstrating mean weight reductions of approximately 13.4% and 15.7% at 10 mg and 15 mg respectively, confirming that the weight-loss effect, though attenuated relative to non-diabetic subjects, remains clinically substantial in T2DM.13
The SURPASS-CVOT trial, which enrolled 13,165 patients with T2DM and established atherosclerotic cardiovascular disease (ASCVD) and reported results in December 2025, demonstrated that tirzepatide was non-inferior to dulaglutide with respect to the three-point major adverse cardiovascular event (MACE) composite of cardiovascular death, myocardial infarction, or stroke, while also showing a 16% reduction in all-cause mortality and greater improvement in renal endpoints compared with dulaglutide. Because the comparator was dulaglutide, a GLP-1R agonist with established cardiovascular benefit, the SURPASS-CVOT results confirm that tirzepatide preserves the cardiovascular protection of the incretin class and does not add cardiovascular risk, positioning it as a safe and metabolically superior choice over a cardioprotective GLP-1R agonist in T2DM patients with ASCVD according to the American Diabetes Association (ADA) comorbidity-driven prescribing framework.5
SURPASS trials: T2DM population, primary endpoint HbA1c reduction, comparators include insulin and semaglutide. SURMOUNT trials: obesity population (SURMOUNT-1: no T2DM; SURMOUNT-2: T2DM), primary endpoint body weight reduction. SURPASS-CVOT: T2DM + established ASCVD, primary endpoint 3-point MACE. Tirzepatide FDA approved for T2DM (Mounjaro, May 2022) and obesity (Zepbound, November 2023).
The weight loss produced by glucagon-like peptide-1 receptor (GLP-1R) agonists and dual incretin agonists is not simply a consequence of nausea or gastric slowing but reflects genuine engagement with the central hypothalamic circuits that regulate long-term energy homeostasis. Understanding these circuits is essential for interpreting the magnitude and durability of pharmacological weight loss and for counseling patients on the expected consequences of treatment discontinuation.
Body weight is regulated by a distributed neuroendocrine system centered on the hypothalamic arcuate nucleus (ARC), which contains two antagonistically acting neuronal populations: neurons co-expressing neuropeptide Y (NPY) and agouti-related peptide (AgRP), which are orexigenic (appetite-promoting), and neurons expressing pro-opiomelanocortin (POMC), which are anorexigenic (appetite-suppressing). NPY/AgRP neurons project to the paraventricular nucleus (PVN) of the hypothalamus and release NPY, which stimulates feeding, and AgRP, which is an inverse agonist at melanocortin 4 receptor (MC4R) and blocks the anorexigenic signal from POMC-derived alpha-melanocyte-stimulating hormone (alpha-MSH). POMC neurons, when activated, release alpha-MSH, which binds MC4R in the PVN and lateral hypothalamus to reduce food intake and increase energy expenditure. The balance between these two populations determines the defended body weight set point.6
GLP-1R is expressed on both NPY/AgRP and POMC neurons in the ARC, and GLP-1R agonism at these sites shifts the balance toward reduced appetite: GLP-1R activation suppresses NPY/AgRP neuron firing and enhances POMC neuron activity, driving MC4R-mediated anorexigenic signaling. GLP-1R is also expressed in the nucleus tractus solitarius (NTS) of the brainstem, which receives vagal afferent signals from gut mechanoreceptors and chemoreceptors and relays satiety information to the hypothalamus. Pharmacological GLP-1R agonism at NTS neurons amplifies these vagal satiety signals, reducing meal size and frequency independently of the hypothalamic arc. The combined hypothalamic and brainstem actions of GLP-1R agonism account for the appetite suppression and early satiety that are the primary drivers of weight loss in clinical trials.7
The adipostat concept explains why pharmacological weight loss with incretin agents is maintained during treatment but rebounds substantially on discontinuation. The hypothalamic energy homeostasis system defends a body weight set point determined by chronic leptin and insulin signaling from peripheral fat mass and pancreatic beta cells respectively. When body weight falls, leptin and insulin levels decline, increasing the orexigenic drive from NPY/AgRP neurons and decreasing anorexigenic POMC signaling, producing a compensatory increase in appetite and reduction in energy expenditure that resists further weight loss. GLP-1R agonism overrides this homeostatic resistance by pharmacologically suppressing NPY/AgRP drive and augmenting POMC activity, maintaining weight loss against the background of falling leptin. When the drug is stopped, the pharmacological override is removed, the full orexigenic rebound is unmasked, and body weight returns toward the defended set point, typically recovering most of the lost weight within twelve months of discontinuation as demonstrated in the Semaglutide Treatment Effect in People with obesity (STEP) 1 extension trial for semaglutide.7
Glucose-dependent insulinotropic polypeptide receptor (GIPR) is also expressed in hypothalamic neurons, including in the ARC and ventromedial hypothalamus, and GIPR agonism in the central nervous system (CNS) contributes independently to the appetite suppression and weight loss observed with tirzepatide. Rodent studies using CNS-specific GIPR knockouts demonstrate that central GIPR signaling is required for the full weight-loss effect of tirzepatide, and human neuroimaging data suggest that glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GIP/GLP-1) dual agonism produces greater attenuation of food-cue-evoked brain reward responses than GLP-1R agonism alone. This central GIPR contribution to appetite suppression is the most pharmacologically compelling explanation for tirzepatide’s weight-loss superiority over semaglutide at doses where the two drugs produce comparable GLP-1R activation.2
Weight regain after GLP-1R agonist discontinuation is a pharmacological expectation, not a treatment failure. Counsel patients that these agents are chronic therapies analogous to antihypertensives: stopping the drug removes the pharmacological override of the weight-defending set point. For patients who must discontinue (cost, side effects, surgery), anticipate and plan for weight regain with behavioral support and re-initiation strategies where feasible.
The striking metabolic outcomes with tirzepatide have accelerated development of next-generation agents targeting additional receptor pathways. Three mechanistic strategies are most advanced in clinical development: glucagon receptor co-agonism added to glucagon-like peptide-1 receptor/glucose-dependent insulinotropic polypeptide receptor (GLP-1R/GIPR) agonism (triple agonism), amylin receptor agonism combined with GLP-1R agonism, and oral small-molecule GLP-1R agonists that eliminate the need for subcutaneous injection.
Retatrutide is a single peptide that functions as a triple agonist at the GLP-1R, glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR), the last of which is the primary driver of hepatic glucose production and also promotes hepatic fat oxidation and thermogenesis in brown adipose tissue. Adding GCGR agonism to GLP-1R/GIPR agonism is designed to further amplify weight loss through increased energy expenditure: glucagon receptor activation in the liver upregulates fatty acid oxidation, and in brown adipose tissue it increases thermogenic uncoupling protein-1 (UCP-1) expression, raising basal metabolic rate. The theoretical concern with GCGR agonism is worsening glycemia, since glucagon is a counter-regulatory hormone that raises hepatic glucose output. This is counterbalanced in retatrutide by the dominant GLP-1R-mediated insulin secretion and the suppression of endogenous glucagon by GLP-1R activation. Phase 2 data presented in 2023 demonstrated weight loss of approximately 17.5% at 24 weeks with retatrutide 12 mg weekly in patients with obesity, a rate that, if sustained through 72 weeks, would substantially exceed tirzepatide outcomes; phase 3 trials are ongoing.8
Cagrilintide is a long-acting amylin analog designed for once-weekly subcutaneous injection. Amylin, co-secreted with insulin from pancreatic beta cells, activates amylin receptors in the area postrema and nucleus tractus solitarius (NTS) of the brainstem to slow gastric emptying, suppress glucagon, and reduce food intake. The native peptide pramlintide, approved for use with insulin in type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM), requires thrice-daily injection and produces modest weight loss of 2 to 4 kg; cagrilintide is engineered with a fatty acid chain for albumin binding that extends its half-life to approximately one week. In the CagriSema combination trials, cagrilintide 2.4 mg was combined with semaglutide 2.4 mg weekly (the CagriSema fixed-dose combination) and evaluated in phase 2 trials in patients with obesity. At 32 weeks, mean weight loss with CagriSema was approximately 15.6% compared with approximately 5.1% for cagrilintide alone and approximately 8.0% for semaglutide alone, demonstrating substantial additive effect when amylin and GLP-1R pathways are simultaneously activated. The phase 2 results provided the efficacy and safety basis for phase 3 CagriSema trials now in progress.9
Oral non-peptide GLP-1R agonists represent a distinct chemical class from the injectable peptide-based agents. Orforglipron and danuglipron are small-molecule GLP-1R agonists that can be administered as daily oral tablets without the absorption enhancers required for oral semaglutide (which is a peptide requiring sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC) coformulation and strict fasting administration). Small-molecule GLP-1R agonists bind the receptor at a site partially overlapping with the orthosteric peptide-binding domain but do not require the complex conformational changes associated with peptide agonism, and their oral bioavailability derives from conventional small-molecule absorption in the small intestine rather than specialized permeation enhancers. Phase 2 data for orforglipron showed weight loss of approximately 9 to 12% at 26 weeks in patients with obesity and HbA1c reductions of approximately 1.5 to 2.1% in T2DM, with a gastrointestinal adverse effect profile similar to injectable GLP-1R agonists. Phase 2 results for both agents provided the basis for phase 3 trials now underway; the commercial availability of effective oral non-peptide GLP-1R agonists would markedly expand the population able to access this therapeutic class by eliminating injection barriers.10
Retatrutide (GLP-1/GIP/glucagon triple agonist): Phase 3 trials ongoing as of 2024. Not yet FDA approved. Cagrilintide + semaglutide (CagriSema): Phase 3 trials ongoing. Not yet FDA approved. Orforglipron (oral small-molecule GLP-1R agonist): Phase 3 trials ongoing. Danuglipron (oral small-molecule GLP-1R agonist): Phase 3 trials ongoing. Do not prescribe these agents outside of clinical trials; cite only published phase 2 data when discussing with patients.
Tirzepatide has demonstrated clinically meaningful benefit beyond glycemic control and weight reduction in two conditions that frequently accompany type 2 diabetes mellitus (T2DM) and obesity: metabolic dysfunction-associated steatohepatitis (MASH), formerly designated non-alcoholic steatohepatitis (NASH), and heart failure with preserved ejection fraction (HFpEF). These effects reflect the hepatic and cardiac consequences of improving insulin sensitivity, reducing visceral adiposity, and attenuating adipose tissue-driven systemic inflammation.
Metabolic dysfunction-associated steatohepatitis (MASH) is characterized by hepatic steatosis accompanied by lobular inflammation, hepatocellular ballooning, and varying degrees of fibrosis, and represents the progressive form of metabolic-associated steatotic liver disease (MASLD). It is strongly associated with obesity, T2DM, and insulin resistance, and can progress to cirrhosis and hepatocellular carcinoma in a significant minority of patients. The Synergy NASH trial (SYNERGY-NASH) was a phase 3 randomized controlled trial that evaluated tirzepatide 5 mg, 10 mg, and 15 mg weekly versus placebo in 190 patients with biopsy-confirmed MASH and fibrosis stage F2 (bridging fibrosis) or F3 (advanced fibrosis). At 52 weeks, MASH resolution without worsening of fibrosis was achieved in 44%, 56%, and 62% of patients receiving tirzepatide 5, 10, and 15 mg respectively, compared with 10% in the placebo group. Fibrosis improvement by at least one stage was observed in 55%, 51%, and 51% of tirzepatide-treated patients versus 30% with placebo. These response rates substantially exceeded those seen with pioglitazone, the only previously available agent with demonstrated histological efficacy in MASH, and are comparable to or exceed those of semaglutide in the NASH phase 2 trial, establishing tirzepatide as a leading agent for MASH pharmacotherapy pending full regulatory review.11
Heart failure with preserved ejection fraction (HFpEF), defined as symptomatic heart failure with a left ventricular ejection fraction (LVEF) of 50% or greater, accounts for approximately half of all heart failure cases and is strongly associated with obesity, hypertension, and T2DM. Obesity-related HFpEF is mechanistically driven by epicardial fat infiltration, pericardial constraint, neurohormonal activation, and impaired myocardial relaxation from lipotoxicity and inflammation.
The Semaglutide and Tirzepatide in Cardiac and Metabolic Disease – Heart Failure with Preserved Ejection Fraction trial (SUMMIT) evaluated tirzepatide 2.5 to 15 mg weekly titrated to maximum tolerated dose versus placebo in 731 patients with HFpEF and body mass index (BMI) of 30 or greater. The primary composite endpoint of cardiovascular death or worsening heart failure events was reduced by 38% with tirzepatide compared with placebo (hazard ratio 0.62, 95% confidence interval 0.41 to 0.95), with a mean body weight reduction of 9.9% in the tirzepatide group versus 0.7% with placebo at 52 weeks. Kansas City Cardiomyopathy Questionnaire (KCCQ) scores, a validated measure of heart failure symptom burden and quality of life, improved significantly more with tirzepatide than placebo. The SUMMIT results complement those of the Semaglutide Treatment Effect in People with obesity – Heart Failure with Preserved Ejection Fraction (STEP-HFpEF) trial, which demonstrated similar symptomatic and functional benefits with semaglutide 2.4 mg weekly in HFpEF patients with obesity, establishing glucagon-like peptide-1 (GLP-1)-based dual and mono agonism as effective therapies for obesity-related HFpEF.1214
The comparison between tirzepatide and pioglitazone for MASH is clinically relevant because pioglitazone, a peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist, has been the most widely studied pharmacological agent for MASH histology and is included in American Diabetes Association (ADA) and liver disease guidelines as an option for MASH in patients with T2DM. Pioglitazone produces MASH resolution in approximately 30 to 40% of treated patients in clinical trials, which is lower than the 44 to 62% response range seen with tirzepatide in SYNERGY-NASH. However, the comparison is not direct because pioglitazone trials used older histological criteria and different patient populations. Pioglitazone also promotes weight gain (3 to 4 kg), fluid retention, and bone loss, whereas tirzepatide produces substantial weight loss that itself ameliorates hepatic steatosis and inflammation. For patients with T2DM and MASH who require pharmacological MASH therapy, tirzepatide offers the combined advantages of glycemic control, weight reduction, and direct hepatic benefit without the adverse metabolic profile of pioglitazone.11
Both trials enrolled HFpEF patients with obesity (BMI ≥30). SUMMIT (tirzepatide): 38% reduction in CV death/worsening HF events; 9.9% weight loss. STEP-HFpEF (semaglutide 2.4 mg): no significant reduction in CV death/worsening HF events as a combined endpoint, but significant improvements in KCCQ score, 6-minute walk distance, and body weight. Both drugs reduce symptom burden in obesity-related HFpEF. SGLT-2 inhibitors remain the agents with the strongest evidence for HFpEF outcomes regardless of obesity status.
Translating the clinical trial evidence for tirzepatide into practice requires familiarity with its dose titration schedule, the basis for preferring it over glucagon-like peptide-1 receptor (GLP-1R) agonist monotherapy in specific patient contexts, the management of its combination with insulin, and the real-world access barriers that frequently determine which agent a patient actually receives.
Tirzepatide is initiated at 2.5 mg subcutaneously once weekly and increased by 2.5 mg every four weeks as tolerated, targeting the lowest effective dose. The approved doses are 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg weekly; the maximum dose is 15 mg. The slow four-week titration interval is designed to allow gastrointestinal accommodation and minimize nausea, vomiting, and diarrhea, which are the most common adverse effects and the primary reason for dose reduction or discontinuation. In clinical trials, nausea was reported in approximately 17 to 22% of patients at the 15 mg dose but was predominantly mild to moderate and transient, with most patients tolerating dose escalation to 10 or 15 mg over 20 to 24 weeks. The injection site for tirzepatide can be the abdomen, thigh, or upper arm, and should be rotated at each injection to avoid lipodystrophy. Storage requirements are identical to those of other GLP-1R agonists: refrigeration at 2 to 8 degrees Celsius, with the option for room temperature storage for up to 21 days after first use.15
The selection between tirzepatide and a selective GLP-1R agonist (semaglutide or liraglutide) as the preferred incretin-based agent depends on the primary therapeutic goal and patient-specific factors. When the dominant objective is maximal HbA1c reduction in type 2 diabetes mellitus (T2DM), tirzepatide at 10 to 15 mg produces HbA1c reductions of 2.1 to 2.3%, which exceed those of semaglutide 1 mg (approximately 1.8%) and semaglutide 2 mg (approximately 2.0%), making tirzepatide the preferred choice when near-normalization of glycemia is the target. When the dominant objective is body weight reduction, tirzepatide at 15 mg produces approximately 20 to 22% weight loss in non-diabetic obesity and approximately 15% in T2DM, compared with approximately 15% and 10% respectively for semaglutide 2.4 mg, again favoring tirzepatide. When the objective is cardiovascular risk reduction in patients with established atherosclerotic cardiovascular disease (ASCVD), both tirzepatide (SURPASS-CVOT) and semaglutide (SUSTAIN-6, SOUL) have demonstrated major adverse cardiovascular event (MACE) reduction, and selection can be guided by cost, tolerability, and formulary availability rather than differential efficacy.35
The combination of tirzepatide with basal insulin was evaluated in the Semaglutide and Tirzepatide in Type 2 Diabetes 6 trial (SURPASS-6), which randomized 1,428 patients with T2DM inadequately controlled on basal insulin plus oral agents to tirzepatide 5 mg, 10 mg, or 15 mg weekly or insulin lispro three times daily, with concurrent titration of basal insulin in both arms. Tirzepatide produced superior HbA1c reductions (2.1%, 2.4%, and 2.6% for the three doses vs 1.4% for insulin lispro) and was associated with significantly lower rates of hypoglycemia (documented symptomatic hypoglycemia: approximately 10 to 19% with tirzepatide vs 46% with insulin lispro) and greater weight loss. When combining tirzepatide with basal insulin in clinical practice, basal insulin doses typically require reduction by 20% at tirzepatide initiation to mitigate hypoglycemia risk, with further titration guided by fasting glucose monitoring. Tirzepatide should not be combined with other GLP-1R agonists or with pramlintide, as the overlapping mechanisms provide no additive benefit and increase adverse effect risk.15
Cost and access represent the dominant real-world barriers to tirzepatide use. The list price of tirzepatide (Mounjaro for T2DM, Zepbound for obesity) in the United States exceeded $1,000 per month as of 2024, and insurance coverage is highly variable: while most commercial plans cover Mounjaro for T2DM with a documented HbA1c above threshold, coverage for Zepbound for obesity is inconsistent and many Medicare Part D plans exclude obesity drugs under existing federal statute. Compounded semaglutide and tirzepatide, produced during FDA shortage periods, represent a lower-cost option but carry quality assurance concerns and are not FDA-approved. For patients without adequate coverage, manufacturer savings programs (Lilly Savings Card for Mounjaro/Zepbound) can substantially reduce out-of-pocket costs for commercially insured patients but do not apply to government-insured patients. Prescribers should document medical necessity explicitly, include T2DM diagnosis codes, HbA1c values, and comorbidities such as ASCVD or obesity-related HFpEF when seeking prior authorization, as these comorbidities strengthen the coverage case under most insurer criteria.15
Tirzepatide shares the class contraindications of GLP-1R agonists. Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2). Not for use in type 1 diabetes mellitus (T1DM) as sole glucose-lowering therapy. Use with caution in patients with prior pancreatitis. Gastroparesis or severe gastrointestinal dysmotility: relative contraindication given gastric-emptying slowing effect. Pregnancy: discontinue at least two months before planned conception; insulin is the preferred agent in pregnancy.
Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3–14.
doi:10.1016/j.molmet.2018.09.009Nauck MA, D’Alessio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovasc Diabetol. 2022;21(1):169.
doi:10.1186/s12933-022-01604-7Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503–515.
doi:10.1056/NEJMoa2107519Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–216.
doi:10.1056/NEJMoa2206038Nicholls SJ, Pavo I, Bhatt DL, et al. Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes (SURPASS-CVOT). N Engl J Med. 2025;393(24):2409–2420.
doi:10.1056/NEJMoa2505928Cone RD. Anatomy and regulation of the central melanocortin system. Nat Neurosci. 2005;8(5):571–578.
doi:10.1038/nn1455Drucker DJ. GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab. 2022;57:101351.
doi:10.1016/j.molmet.2021.101351Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514–526.
doi:10.1056/NEJMoa2301972Frias JP, Deenadayalan S, Erichsen L, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2023;402(10403):720–730.
doi:10.1016/S0140-6736(23)01163-7Frias JP, Hsia S, Eyde S, et al. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet. 2023;402(10400):472–483.
doi:10.1016/S0140-6736(23)01302-8Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024;391(4):299–310.
doi:10.1056/NEJMoa2401943Packer M, Zile MR, Kramer CM, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity (SUMMIT). N Engl J Med. 2025;392(5):427–437.
doi:10.1056/NEJMoa2410027Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613–626.
doi:10.1016/S0140-6736(23)01200-XKosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069–1084.
doi:10.1056/NEJMoa2306963American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes — 2024. Diabetes Care. 2024;47(Suppl 1):S1–S321.
doi:10.2337/dc24-SINT